Atormac
Neurology India
Open access journal indexed with Index Medicus
  Users online: 441  
 Home | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe Videos Etcetera Contact
  Navigate Here 
 Search
 
  
 Resource Links
  »  Similar in PUBMED
 »Related articles
  »  Article in PDF (657 KB)
  »  Citation Manager
  »  Access Statistics
  »  Reader Comments
  »  Email Alert *
  »  Add to My List *
* Registration required (free)  

 
  In this Article
 »  Abstract
 » Procedure
 »  Clinical Feature...
 »  Impulsive–...
 » Management
 » Conclusion
 »  References
 »  Article Tables

 Article Access Statistics
    Viewed367    
    Printed2    
    Emailed0    
    PDF Downloaded32    
    Comments [Add]    

Recommend this journal

 


 
Table of Contents    
REVIEW ARTICLE
Year : 2018  |  Volume : 66  |  Issue : 4  |  Page : 967-975

Impulse control disorders in Parkinson's disease: Review of pathophysiology, epidemiology, clinical features, management, and future challenges


Department of Neurology, Royal Cornwall Hospital NHS Trust, Cornwall, Truro, UK

Date of Web Publication18-Jul-2018

Correspondence Address:
Dr. Shakya Bhattacharjee
Department of Neurology, Royal Cornwall Hospital NHS Trust, Cornwall, Truro
UK
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0028-3886.237019

Rights and Permissions

 » Abstract 


Impulsive–compulsive behavior (ICB) in Parkinson's disease (PD) suggests a combination of impulse control disorders (ICDs), such as pathological gambling, hypersexuality, compulsive eating, excessive buying, and compulsive behaviors, such as punding, dopamine dysregulation syndrome (DDS), hoarding, and hobbyism. Hypersexuality and gambling are common in male patients while compulsive buying is common in women patients. Recent studies reveal the prevalence of ICB to be more than 25% among the PD patients. The nigrostriatal, mesocortical, and mesolimbic dopaminergic pathways play a crucial role in the pathogenesis of ICDs in PD patients. The greater tonic release of dopamine creates a state of relative dopamine deficit and reduced reward sensation and impulsive behaviors. The major risk factors for ICB are the use of dopamine agonist (DA), male gender, young patient, depression, smoking, drug abuse, Parkin mutation, and family history of ICDs. Single nucleotide polymorphism in dopamine receptors D1, D2, and D3 also acts as a major risk factor. Questionnaire for impulsive–compulsive disorders in PD is the most widely adopted screening tool for the detection of ICB in PD. The major treatment for PD is to discontinue DAs and use prolonged release formulation of the DAs. The role of deep brain stimulation (DBS) and apomorphine in the treatment of ICB is still uncertain. Though DBS can reduce the risk of DDS, it can precipitate new ICBs such as hypersexuality.


Keywords: Behavior, compulsive, dopamine, impulsive, Parkinson's disease
Key Message: Impulsive–compulsive behavior (ICB) in Parkinson′s disease (PD) remains a global health problem and is a manifestation of a combination of impulse control disorders (ICDs), such as pathological gambling, hypersexuality, compulsive eating, excessive buying, and compulsive behaviors, such as punding, dopamine dysregulation syndrome (DDS), hoarding, and hobbyism. As literature has revealed a wide discrepancy in the ICD prevalence with various ICD questionnaires, all ICD screening instruments need prospective, multicenter, cross‑validation studies. The influence of the dose of levodopa, ethnicity, and genetic polymorphism as well as that of deep brain stimulation and apomorphine administration on the generation and prevalence of ICD need to be investigated.


How to cite this article:
Bhattacharjee S. Impulse control disorders in Parkinson's disease: Review of pathophysiology, epidemiology, clinical features, management, and future challenges. Neurol India 2018;66:967-75

How to cite this URL:
Bhattacharjee S. Impulse control disorders in Parkinson's disease: Review of pathophysiology, epidemiology, clinical features, management, and future challenges. Neurol India [serial online] 2018 [cited 2018 Aug 17];66:967-75. Available from: http://www.neurologyindia.com/text.asp?2018/66/4/967/237019




Impulse control disorders (ICDs) or impulsive–compulsive behaviors (ICBs) suggest an inability to curb the urge or temptation to perform an act which is detrimental to oneself or others.[1],[2] Recent study shows that the prevalence of ICB can be more than 25% among the idiopathic Parkinson's disease (PD) population.[1] ICDs in PD generally suggest one of the four major disorders: pathological gambling (PG), hypersexuality, compulsive eating, and excessive buying/shopping, whereas some closely related phenomena such as punding, dopamine dysregulation syndrome (DDS), hoarding, and hobbyism are generally included under the broader heading of ICBs.[1],[2] PG and hypersexuality are more common in male PD patients while excessive shopping is commoner in female PD patients.[2]


 » Procedure Top


Pathophysiology of ICDs

The nigrostriatal, mesocortical, and mesolimbic dopaminergic pathways play a crucial role in the pathogenesis of ICB in PD patients. Long-term use of dopamine agonists (DAs) results in downregulation of the dopamine 2 (D2) receptors expression.[2] Consequently, the PD patients seek higher than normal stimuli to obtain sufficient rewards. Moreover, the limbic area, including the nucleus accumbens area which controls the reward and emotions, contains greater numbers of D3 receptors. DA drugs preferentially act on these D3 receptors while levodopa targets D1/D2 receptors. The D1/D2 receptors are abundant in the caudate nucleus and putamen. The caudate nucleus and putamen have no major role in impulse control and reward-seeking behaviors, so levodopa poses a lesser risk of ICD. The second possible reason is the greater tonic dopamine release and reduced phasic release. Any action of greater uncertainty such as a buying spree triggers the tonic dopamine release but the phasic release of dopamine occurs when a reward is anticipated. This phasic dopamine release is suppressed when the reward is not granted. The greater tonic release of dopamine will lead to a relative dopamine deficit and reduced reward sensation.

The role of genetic polymorphism in the genesis of ICB

Single nucleotide polymorphism (SNP) in dopaminergic receptors D1, D2, and D3 and glutamate receptor N-methyl-D-aspartate (NMDA) are the two most widely studied pathways for PD-ICD.[2] The GRIN 2B (Glutamate [NMDA] receptor subunit epsilon-2) variant is the most important of the NR2 [NMDA receptor 2] subtypes of NMDA receptor where SNP was found to have an association with the risk of ICD.[3] GRIN 2B is more commonly expressed in striatum. Hydroxytryptamine receptor (HTR2A), dopa decarboxylase (DDC), and dopamine transporter 1 (DAT1) gene polymorphism were also found to have an association with PD-related ICD. Krishnamoorthy et al.,[4] recently observed a novel association between the dopamine receptor type 3 (DRD3) p.S9G(rs6280) CT genotype and the ICD trait in a cohort of Indian PD patients. A large prospective study concluded that the role of DRD3 polymorphism on the risk of ICD in the Caucasian PD population was insignificant.[5] Kraemmer et al.,[6] suggested that the opioid receptor kappa 1 (OPRK1) rs702764: TC genotype increases the risk of ICD in the whole PD population. However, the OPRK1 genotypes rs702764: TC and rs702764: CC, HTR2A genotype rs6313: GA and rs6313: AA, DDC genotype rs383709: -/AGAG, rs3837091: -/- and rs1451375: AA, all increased the risk of ICD in PD patients using DA. One review found no association of the DAT gene SLC6A4 gene or the catechol O-methyl transferase (COMT) gene Val158 Met with PD-related ICD.[7]

The DRD1 rs4867798, DRD1 rs4532, DRD2/ANKK1 rs1800497, and GRIN2B rs7301 but not D4/D5 receptor polymorphism were associated with increased risk of developing ICD among 91 Malaysian PD patients.[3] A South Korean study found that the variants of DRD2 and 5-HTTLPR were not associated with the risk of developing ICD.[8] The impact of the c. 102T>C variant was significantly enhanced in the lower levodopa equivalent dose (LED) group, increasing the risk of ICDs by 2.8 and 6.9 times in CT and TT carriers, respectively. However, the c. 102T>C variant had no statistically significant effect on the development of ICDs in the higher LED group.[9] An Italian study found no association between the COMT Met/met genotype, DRD2 Taq1A, and DAT1 polymorphism and the risk of developing ICDs in PD patients.[10] Hoenicka et al.,[11] analyzed the role of addiction-related gene ankyrin repeat and kinase domain containing 1 and found no association between the Taq1A SNP and ICD. The PD patients with GRIN 2B c.2664C>T genotype “AG” preferred the high-frequency of gain disadvantageous deck of the Iowa Gambling Task (test for ICD).[12] [Table 1] summarizes the research studies on genetic polymorphism related to ICDs in PD.[13]
Table 1: Literature review on genetic variations and the risk of impulse control disorders in Parkinson's disease patients

Click here to view


The genetic studies on ICD need to adopt a multiethnic and integrated approach to include dopaminergic, serotonergic, glutamatergic, and opioid pathways as the emerging evidences suggest the influence of multiple factors in the development of ICD. The effect of genetic polymorphism can only be accurately assessed when the PD patients (the controls) are also treated with similar doses of DAs as the cases with ICD in order to have comparable dopaminergic state in both the groups.[13] Genetic polymorphism plays an important role in the generation of ICD in the lower LED PD group but not in the higher dose group.

Epidemiology and risk factors

The common ICDs reported are compulsive eating, buying, gambling, sexual behaviors, and lately, the cyber addictions [1],[2],[14],[15],[16],[17],[18],[19] [Table 2]. The major risk factors for ICB in PD patients are use of DAs, male gender, young patient, depression, smoking, drug abuse, genetic factors, and family history of ICDs [Table 2]. PD patients with Parkin mutations showed a higher frequency of ICBs with DAs, pramipexole and ropinirole, though longer-acting formulations of the DAs and rotigotine were less likely to result in ICB.[18],[20] Male patients are more prone to hypersexuality and eating disorders while compulsive shopping is commoner among female patients across Europe, North America, and Asia.[2],[21] The prevalence of ICD was found to be 6–43% patients in many studies from North and Latin America, Asia, and Europe [Table 3].[14],[17],[18],[22],[23],[24],[25],[26],[27] The largest ICD study on PD patient conducted so far (DOMINION study in US and Canada) involving 3090 patients reported a 6-monthly ICD prevalence of 13.6%.[18] The nature of ICD varied widely across countries. Pathological gambling was the commonest ICD in North American PD patients (5%), compulsive medication use in China (11.3%), punding (12.4%) and hypersexuality (11.04%) in India, hypersexuality in Finland, hobbyism and punding in Denmark, etc. [Table 3]. The prevalence of the type of ICD or ICB can be influenced by the cultural, religious, and socioeconomic factors, e.g., pathological gambling is likely to be less prevalent or underreported in India and China as public gambling or casino visiting is not a socially accepted custom in these countries.[2],[14],[18],[27],[28]
Table 2: Risk factors for impulse control disorders in Parkinson's disease

Click here to view
Table 3: Prevalence of major impulsive compulsive behaviours (ICB) in PD in various parts around the world

Click here to view


Recent studies show that ICB has a higher prevalence in young unmarried male subjects and in patients with a longer duration of the disease.[1],[2],[18],[27],[28] The motor performance, Hoehn and Yahr (H&Y) stages, as well as cognitive faculties were similar in the ICD and the non-ICD PD patients but the ICD group had a higher prevalence of nonmotor symptoms, including depression, sleep disorders, and higher scores in the non-motor symptoms assessment scale Non Motor Symptoms Scale (NMSS) across many domains. The ICD patients showed higher scores in sleep disorders, fatigue, and sexual dysfunction. However, a higher prevalence of depression in PD-ICD patients might explain symptoms such as tiredness, apathy, or sleep disorders.[1] ICD patients had a higher educational qualification and a greater tendency to indulge in substance abuse in the Italian population.[2] However, a recent study from China showed no statistically significant difference in educational achievements between ICB positive and negative PD patients.[14] The prevalence of ICD was higher in patients on combined levodopa and DAs than in patients on levodopa or DA alone. The development of ICD in PD is far more complex than its development when DA is used alone.


 » Clinical Features of Impulse Control Disorders Top


Pathological gambling

Pathological gambling was one of the earliest ICDs to be described. Pathological gambling is inappropriate, recurrent, and persistent maladaptive gambling activity that adversely affects family, personal, and professional life.[29] The prevalence of pathological gambling is between 4 and 8% and is higher among the US PD patients with ICD.[2],[18],[28],[30] The prevalence is higher in DA users. The preferred gambling methods described include slot machines, internet gambling, and gambling techniques, which are repetitive, require less cortical processing, and high reward uncertainty.[2] High reward uncertainty is a characteristic of tonic ventral tegmental area neural activity. Often gamblers develop ritualistic behaviors such as lucky charms, lucky clothes, etc., to improve their chances of winning.[31]

Hypersexuality

Compulsive sexual behavior is excessive and distressing sexual thoughts persisting for more than 1 month that interfere with social and occupational activity.[2],[28],[32] Compulsive sexual behaviors involve excessive preoccupation with sexual thoughts, internet pornography, desire for frequent genital stimulation, promiscuity and telephone sex, etc., and are often underreported. Their prevalence is stated to be more than 4% in DA users and almost 2% in PD patient not taking DAs. Related behaviors such as zoophilia, change in sexual preference, and paraphilia were also reported in the literature.[28],[33]

Excessive eating

Compulsive eating is consumption of large amounts of food more than once than is usually needed to alleviate hunger without any associated purging behavior.[2],[28],[29] According to the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV), this disorder involves eating until one is feeling uncomfortably full, or solitary eating because of shame or disgusted self-image about the eaten quantity. PD patients usually lose weight during the early stages.[34] However, compulsive eating can trigger significant weight gain and thus further reduce mobility.

Compulsive buying or shopping

Compulsive buying is seen in more than 3% of PD population and is more common in women.[2] It is seen in more than 7% of the DA users.[35] Compulsive shopping can cause significant financial and social distress.[2],[28] These habits are irresistible, intrusive, time-consuming, and distressing.


 » Impulsive–compulsive Behaviors Top


The major ICBs found in PD are punding, hoarding, DDS, and hobbyism.

Punding

Punding generally refers to intense fascination to repeatedly manipulate, examine, or handle technical equipment or common objects along with an extended involvement in monologues devoid of contents.[2],[28],[36],[37],[38] Patients with punding have a higher rate of obsessive compulsive traits than is present in control subjects. Punding is classified as a compulsive behavior as this does not lead to satisfaction or joy, and performance of the act leads to relief.[2],[38] The higher prevalence of dyskinesia among PD patients with punding suggests a similar mechanism. One study in the UK found that the prevalence of punding was more than 14% in people with an intake of >800 mg/day LED.[39]

Dopamine Dysregulation syndrome

DDS is a form of addiction where people with PD need abnormally higher dose of dopamine replacement therapy (DRT) for their parkinsonism.[29],[40] The need for dopamine replacement gets progressively worse. During the on-phase, patients can go for “walkabouts.”[2],[41] Often the dysphoria and anxiety during the withdrawal phase is coupled with an aggressive demand for DRT.[2] Patients with previous mood disorders are more prone to have the DDS. Though DDS can be seen with both DRT and DA, the risk is much higher with levodopa and apomorphine.

Hoarding

Hoarding suggests acquiring or failure to discard a large number of substances of no or little value.[28],[29] Often, this habit results in an inhabitable condition for family members. Hoarding like other ICBs can lead to significant distress to other family members. Hoarding of levodopa or DAs can be found in people with DDS.

Miscellaneous compulsive behaviors

Hobbyism suggests repetitive and excessive complex motor activities such as writing, gardening, collecting, use of internet, etc. Walkabout is a form of restlessness leading to aimless and excessive wandering (walking or driving). Miscellaneous impulsive behaviors reported include locking and unlocking doors, excessive generosity, reckless driving, excessive smoking and drug addiction, and recurrent pet killing (in a juvenile PD patient).[2],[28] One patient developed compulsive drumming and beating of percussion instruments following pramipexole therapy, and one developed a habit of compulsive singing after DRT.[42],[43]

Screening tools for Impulse Control Behaviors

Various rating scales and questionnaires are available to assess the ICB in PD [Table 4]. The widely used scales are Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease (QUIP), QUIP Rating Scale Version (QUIP-RS), Modified Minnesota Impulsive Disorders Interview, Dopamine Dysregulation Syndrome-Patient and Caregiver Inventory, Parkinson's Impulse Control Scale.[44],[45],[46],[47],[48] The Scale for Outcome in Parkinson Disease Psychiatric Complications is also a validated screening tool for psychiatric complications in PD.[49] A separate questionnaire for punding and gambling (South Oak Gambling Screen) is also available.[38],[50]
Table 4: The assessment tools for ICB diagnosis and the treatment options for ICD related to PD

Click here to view


QUIP, the most widely studied questionnaire for ICB in PD, has 30 questions. QUIP was found to be 100% sensitive and specific when filled by both patients and informants. QUIP-RS is also a validated compact version of the QUIP and can be used to monitor changes over time.[2]


 » Management Top


Medical

The medical management is summarized in [Table 4]. The main medical management of ICB remains either discontinuation of DAs or switching to a DA with lesser risk of ICBs. The DOMINIAN study found both levodopa and dopamine to be independent risk factors for ICD.[18] Driver-Dunckley et al.,[51] noticed that pathological gambling improved when pramipexole was changed to ropinirole, though recently, the DOMINION study found a similar prevalence of ICD between pramipexole and ropinirole users. Burkhard et al.,[52] revealed that ICD symptoms disappeared or decreased when DA was replaced by either subthalamic stimulation or catechol-O-methyltransferase (COMT) inhibitor. Bastiaens et al.,[53] reported that ICB symptoms resolved in all 10 patients who discontinued DA therapy. Mamikonyan et al.,[54] claimed that 83% PD-related ICD patients did not satisfy the diagnostic criteria for ICD after the cessation of DA therapy and their Unified Parkinson's Disease Rating Scale (UPDRS) Motor Score did not change significantly. However, Sohtaoǧlu et al.,[55] contradicted the claim by reporting an increment in the UPDRS score in 74% of PD patients who fully recovered from the ICD. When DAs cannot be withdrawn or reduced, it is preferable to use a longer-acting formulation as the risk of ICD is lower with prolonged release formulation.[20]

The role of amantadine in ICD is controversial. One small study revealed that amantadine abolished or reduced expenditures, due to gambling, by 75–90% in 2–3 days.[56] A few other studies have also reported a higher frequency of ICDs such as hypersexuality and pathological gambling.[21],[57],[58] On the one hand, amantadine had a dopamine-enhancing effect, leading to increased risk of ICD, and on the other hand, it also has an anti-glutaminergic effect protecting the patient from the risk of ICD.[58]

There are anecdotal reports of valproate improving the ICD in 3 PD patients.[59] A small open-level study revealed that topiramate could reduce the severity of impulsive behavior and global impulsiveness.[60] Bermejo et al.,[61] reported that zonisamide reduced the severity of ICD. One case series suggested that clozapine could improve ICD symptoms that persisted even after the cessation of DA therapy.[62] Gerschlager and Bloem [63] demonstrated an interesting example where switching from oral to enteral higher dose of continuous levodopa infusion completely cured gambling and punding after 1 year. The authors suggested the role of pulsatile dopamine release in the generation of ICB.

Apomorphine

A 3-year clinical observational study reported a relatively low rate (9.7%) of new cases on apomorphine infusion with clinically relevant ICD.[64] García Ruiz et al.,[65] reported that only one out of the 82 patients treated with long-term apomorphine therapy developed hypersexuality disorders. In a multicenter open-label prospective study, Martinez-Martin et al.,[66] reported that only 4 patients developed ICD after apomorphine infusion and none needed discontinuation of therapy. A recent 10-year review by Moore et al.,[67] found apomorphine to be least often associated with ICD among all DAs. Though apomorphine infusion looks promising, it needs further study to determine its role in the generation or treatment of ICD.

Deep Brain Stimulation

The role of deep brain stimulation in ICB is not quite clear as studies revealed conflicting results. As a successful DBS can result in levodopa dose reduction, prospective studies claimed that hyperdopaminergic manifestations such as ICDs would reduce post DBS.[2] Ardouin et al.,[68] and Bandini et al.,[69] reported improvement in ICDs after subthalamic nucleus (STN) DBS [Table 5] Shotbolt et al.,[70] reported that ICD in 3 patients completely resolved after the DBS surgery. Lhommée et al.,[71] even claimed that disabling dopaminergic drug overuse and drug-induced behavioral addictions should be included as a new indication for DBS surgery. However, Akakin et al.,[72] described a patient who developed hypersexuality despite motor improvement post DBS. Kim et al.,[73] reported 40% new incidences of ICD after the DBS. In a recent survey, 67% of the Parkinson study group centers observed at least one case of de novo ICD after DBS surgery.[74] Rogers et al.,[75] reported that PD patients with DBS showed a tendency to increase the value of losses that they were willing to play with while gambling, when shifting from the DBS-off to DBS-on conditions. A retrospective analysis conducted by Moum et al.,[76] discovered 17 new cases of ICD after the DBS implantation. The incidences were seen regardless of unilateral or bilateral, or SNT or global pallidus interna (Gpi) stimulation. The DBS improves some ICDs related to the hyperdopaminergic state by reducing dopaminergic drug requirement but can also deactivate the limbic system–basal ganglia loop and hyperactivate ventral striatum to precipitate new ICDs.[2]
Table 5: Studies on the impact of deep brain stimulation (DBS) in impulsive compulsive behaviour in Parkinson's disease

Click here to view


ICD needs a strong defining criteria as it is not always easy to draw a clear line of demarcation between the socially acceptable accentuation of impulsivity and the development of ICD. Most of the ICD studies failed to address the issue of cyber addictions such as video games, online pornography, or gambling etc., as an emerging ICD in PD.[77] The mobile games can provide near constant reinforcement in a PD patient and can lead to more impulsive playing habits. Moreover, the mobile and the internet are easily accessible and socially acceptable so that their use often goes unnoticed till their addiction becomes a major problem in PD. Previously, Wu et al.,[78] revealed that PD patients with ICD have a higher tendency to use the internet in comparison to healthy controls or patients with PD without ICD. A recent study found that self-reporting of ICD symptoms by the PD patients was only 2% though the prevalence of ICD was 27% in PD patients.[79] All ICD screening instruments need prospective, multicenter, cross-validation studies as literature has revealed a wide discrepancy in the ICD prevalence with various ICD questionnaires. The future studies also need to clarify the exact influence of DBS and apomorphine on the ICD incidence and prevalence. Further studies are needed to explore the relationship among the dose of levodopa, ethnicity, and genetic polymorphism in the generation of ICD. Moreover, genetic polymorphism study must be conducted in association with functional neuroimaging and clinical assessment tools to improve the accuracy of ICD risk prediction.[80]


 » Conclusion Top


ICB in PD remains a major global problem. The major risk factors for ICB include a young male patient, previous psychiatric comorbidities, substance abuse, and DAs.

Financial support and sponsorship

Sponsorship: The author received travel grant from Merck Serono Limited, UK to attend dystonia update meeting in London in 2018.

Conflicts of interest

There are no conflicts of interest.



 
 » References Top

1.
Antonini A, Barone P, Bonuccelli U, Annoni K, Asgharnejad M, Stanzione P. ICARUS study: Prevalence and clinical features of impulse control disorders in Parkinson's disease. J Neurol Neurosurg Psychiatry 2017;88:317-24.  Back to cited text no. 1
    
2.
Maréchal E, Denoiseux B, Thys E, Crosiers D, Pickut B, Cras P. Impulse control disorders in Parkinson's disease: An overview from neurobiology to treatment. J Neurol 2015;262:7-20.  Back to cited text no. 2
    
3.
Abidin SZ, Tan EL, Chan SC, Jafaar A, Lee AX, Abd Hamid MH, et al. DRD and GRIN2B polymorphisms and their association with the development of impulse control behaviour among Malaysian Parkinson's disease patients. BMC Neurol 2015;15:1-10.  Back to cited text no. 3
    
4.
Krishnamoorthy S, Rajan R, Banerjee M, Kumar H, Sarma G, Krishnan S, et al. Dopamine D3 receptor Ser9Gly variant is associated with impulse control disorders in Parkinson's disease patients. Parkinsonism Relat Disord 2016;30:13-7.  Back to cited text no. 4
    
5.
McGuire V, Van Den Eeden SK, Tanner CM, Kamel F, Umbach DM, Marder K, et al. Association of DRD2 and DRD3 polymorphisms with Parkinson's disease in a multi-ethnic consortium. J Neurol Sci 2011;307:22-9.  Back to cited text no. 5
    
6.
Kraemmer J, Smith K, Weintraub DL, Guillemot V, Nalls MA, Cormier-Dequaire F, et al. Clinical-genetic model predicts incident impulse control disorders in Parkinson's disease. J Neurol Neurosurg Psychiatry 2016;87:1106-11.  Back to cited text no. 6
    
7.
Napier TC, Corvol JC, Grace AA, Roitman JD, Rowe J, Voon V, et al. Linking neuroscience with modern concepts of impulse control disorders in Parkinson's disease. Mov Disord 2015;30:141-9.  Back to cited text no. 7
    
8.
Lee JY, Lee EK, Park SS, Lim JY, Kim HJ, Kim JS, et al. Association of DRD3 and GRIN2B with impulse control and related behaviors in Parkinson's disease. Mov Disord 2009;24:1803-10.  Back to cited text no. 8
    
9.
Lee JY, Jeon BS, Kim HJ, Park SS. Genetic variant of HTR2A associates with risk of impulse control and repetitive behaviors in Parkinson's disease. Parkinsonism Relat Disord 2012;18:76-8.  Back to cited text no. 9
    
10.
Vallelunga A, Flaibani R, Formento-Dojot P, Biundo R, Facchini S, Antonini A. Role of genetic polymorphisms of the dopaminergic system in Parkinson's disease patients with impulse control disorders. Parkinsonism Relat Disord 2012;18:397-9.  Back to cited text no. 10
    
11.
Hoenicka J, García-Ruiz PJ, Ponce G, Herranz A, Martínez-Rubio D, Pérez-Santamarina E, et al. The addiction-related gene ANKK1 in Parkinsonian patients with impulse control disorder. Neurotox Res 2015;27:205-8.  Back to cited text no. 11
    
12.
Rajan R, Krishnamoorthy S, Krishnan S, Sharma G, Kishore A. A gene for risk taking: Effect of genotypic variants on decision making, response inhibition and impulsivity in Parkinson's disease. Neurology 2016;86:Supplement P4.325.  Back to cited text no. 12
    
13.
Bhattacharjee S. Impulse control disorders in Parkinson's disease: Pathophysiology, effect of genetic polymorphism and future research directions. Austin J Clin Neurol 2017;4:1100-3.  Back to cited text no. 13
    
14.
Zhang Y, He AQ, Li L, Chen W, Liu ZG. Clinical characteristics of impulse control and related disorders in Chinese Parkinson's disease patients. BMC Neurol 2017;17:98.  Back to cited text no. 14
    
15.
Sarathchandran P, Soman S, Sarma G, Krishnan S, Kishore A. Impulse control disorders and related behaviors in Indian patients with Parkinson's disease. Mov Disord 2013;28:1901-2.  Back to cited text no. 15
    
16.
Joutsa J, Martikainen K, Vahlberg T, Voon V, Kaasinen V. Impulse control disorders and depression in Finnish patients with Parkinson's disease. Parkinsonism Relat Disord 2012;18:155-60.  Back to cited text no. 16
    
17.
Callesen MB, Weintraub D, Damholdt MF, Moller A. Impulsive and compulsive behaviors among Danish patients with Parkinson's disease: Prevalence, depression, and personality. Parkinsonism Relat Disord 2014;20:22-6.  Back to cited text no. 17
    
18.
Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V, et al. Impulse control disorders in Parkinson disease: A cross-sectional study of 3090 patients. Arch Neurol 2010;67:589-95.  Back to cited text no. 18
    
19.
Morgante F, Fasano A, Ginevrino M, Petrucci S, Ricciardi L, Bove F, et al. Impulsive-compulsive behaviors in parkin-associated Parkinson disease. Neurology 2016;87:1436-41.  Back to cited text no. 19
    
20.
Rizos A, Sauerbier A, Antonini A, Weintraub D, Martinez-Martin P, Kessel B, et al. A European multicentre survey of impulse control behaviours in Parkinson's disease patients treated with short- and long-acting dopamine agonists. Eur J Neurol 2016;23:1255-61.  Back to cited text no. 20
    
21.
Weintraub D, Claassen DO. Impulse control and related disorders in Parkinson's disease. Int Rev Neurobiol. 2017;133:679-717.  Back to cited text no. 21
    
22.
Sharma A, Goyal V, Behari M, Srivastva A, Shukla G, Vibha D. Impulse control disorders and related behaviours (ICD-RBs) in Parkinson's disease patients: Assessment using “Questionnaire for impulsive-compulsive disorders in Parkinson's disease” (QUIP). Ann Indian Acad Neurol 2015;18:49-59.  Back to cited text no. 22
[PUBMED]  [Full text]  
23.
Rodríguez-Violante M, González-Latapi P, Cervantes-Arriaga A, Camacho-Ordoñez A. Impulse control and related disorders in Mexican Parkinson's disease patients. Parkinsonism Relat Disord 2014;20:907-10.  Back to cited text no. 23
    
24.
Erga AH, Alves G, Larsen JP, Tysnes OB, Pedersen KF. Impulsive and compulsive behaviors in Parkinson's disease: The Norwegian Park West Study. J Parkinsons Dis 2017;7:183-191.  Back to cited text no. 24
    
25.
Tanaka K, Wada-Isoe K, Nakashita S, Yamamoto M, Nakashima K. Impulsive compulsive behaviors in Japanese Parkinson's disease patients and utility of the Japanese version of the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's disease. J Neurol Sci 2013;15:76-80.  Back to cited text no. 25
    
26.
Lim SY, Tan ZK, Ngam PI, Lor TL, Mohamed H, Schee JP, et al. Impulsive-compulsive behaviors are common in Asian Parkinson's disease patients: Assessment using the QUIP. Parkinsonism Relat Disord 2011;17:761-4.  Back to cited text no. 26
    
27.
Valença GT, Glass PG, Negreiros NN, Duarte MB, Ventura LM, Mueller M, et al. Past smoking and current dopamine agonist use show an independent and dose-dependent association with impulse control disorders in Parkinson's disease. Parkinsonism Relat Disord 2013;19:698-700.  Back to cited text no. 27
    
28.
Maloney EM, Djamshidian A, O'Sullivan SS. Phenomenology and epidemiology of impulsive-compulsive behaviours in Parkinson's disease, atypical Parkinsonian disorders and non-Parkinsonian populations. J Neurol Sci 2017;374:47-52.  Back to cited text no. 28
    
29.
Association AP. Diagnostic and Statistical Manual of Mental Disorders. Fifth ed. American Psychiatric Publishing, Washington, DC; 2013.  Back to cited text no. 29
    
30.
Voon V, Hassan K, Zurowski M, Duff-Canning S, de Souza M, Fox S, et al. Prospective prevalence of pathologic gambling and medication association in Parkinson disease. Neurology 2006;66:1750-2.  Back to cited text no. 30
    
31.
Djamshidian A, Cardoso F, Grosset D, Bowden-Jones H, Lees AJ. Pathological gambling in Parkinson's disease—a review of the literature. Mov Disord 2011;26:1976-84.  Back to cited text no. 31
    
32.
Voon V, Hassan K, Zurowski M, de Souza M, Thomsen T, Fox S,et al. Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. Neurology 2006;67:1254-7.  Back to cited text no. 32
    
33.
O'Sullivan SS, Evans AH, Quinn NP, Lawrence AD, Lees AJ. Reckless generosity in Parkinson's disease. Mov Disord 2010;25:221-3.  Back to cited text no. 33
    
34.
Chen H, Zhang SM, Hernán MA, Willett WC, Ascherio A. Weight loss in Parkinson's disease. Ann Neurol 2003;53:676-9.  Back to cited text no. 34
    
35.
McElroy SL, Keck PE Jr., Pope HG Jr., Smith JM, Strakowski SM. Compulsive buying: A report of 20 cases. J Clin Psychiatry 1994;55:242-8.  Back to cited text no. 35
    
36.
Evans AH, Katzenschlager R, Paviour D, O'Sullivan JD, Appel S, Lawrence AD, et al. Punding in Parkinson's disease: Its relation to the dopamine dysregulation syndrome. Mov Disord 2004;19:397-405.  Back to cited text no. 36
    
37.
Voon V. Repetition, repetition, and repetition: Compulsive and punding behaviors in Parkinson's disease. Mov Disord 2004;19:367-70.  Back to cited text no. 37
    
38.
Kumar S. Punding in Parkinson's disease related to high-dose levodopa therapy. Neurol India 2005;53:362.  Back to cited text no. 38
    
39.
Giovannoni G, O'Sullivan JD, Turner K, Manson AJ, Lees AJ. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 2000;68:423-8.  Back to cited text no. 39
    
40.
Ceravolo R, Frosini D, Rossi C, Bonuccelli U. Impulse control disorders in Parkinson's disease: Definition, epidemiology, risk factors, neurobiology and management. Parkinsonism Relat Disord 2009:15;S111-5.  Back to cited text no. 40
    
41.
Lim SY, O'Sullivan SS, Kotschet K, Gallagher DA, Lacey C, Lawrence AD, et al. Dopamine dysregulation syndrome, impulse control disorders and punding after deep brain stimulation surgery for Parkinson's disease. J Clin Neurosci 2009;16:1148-52.  Back to cited text no. 41
    
42.
Vitale C, Trojano L, Barone P, Errico D, Agosti V, Sorrentino G, et al. Compulsive drumming induced by dopamine agonists in Parkinson's disease: Another aspect of punding. Behav Neurol 2013;27:559-62.  Back to cited text no. 42
    
43.
Bonvin C, Horvath J, Christe B, Landis T, Burkhard PR. Compulsive singing: Another aspect of punding in Parkinson's disease. Ann Neurol 2007;62:525-8.  Back to cited text no. 43
    
44.
Papay K, Mamikonyan E, Siderowf AD, Duda JE, Lyons KE, Pahwa R, et al. Patient versus informant reporting of ICD symptoms in Parkinson's disease using the QUIP: Validity and variability. Parkinsonism Relat Disord 2011;17:153-5.  Back to cited text no. 44
    
45.
Weintraub D, Hoops S, Shea JA, Lyons KE, Pahwa R, Driver-Dunckley ED, et al. Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease. Mov Disord 2009;24:1461-7.  Back to cited text no. 45
    
46.
Christenson GA, Faber RJ, de Zwaan M, Raymond NC, Specker SM, Ekern MD, et al. Compulsive buying: Descriptive characteristics and psychiatric comorbidity. J Clin Psychiatry 1994;55:5-11.  Back to cited text no. 46
    
47.
Cabrini S, Baratti M, Bonfà F, Cabri G, Uber E, Avanzi M. Preliminary evaluation of the DDS-PC inventory: A new tool to assess impulsive-compulsive behaviours associated to dopamine replacement therapy in Parkinson's disease. Neurol Sci 2009;30:307-13.  Back to cited text no. 47
    
48.
Okai D, Askey-Jones S, Mack J, Martin A, Chaudhuri KR, Samuel M, et al. Parkinson's impulse-control scale for the severity rating of impulse-control behaviors in Parkinson's disease: A semistructured clinical assessment tool. Mov Disord Clin Pract 2016;3:494-9.  Back to cited text no. 48
    
49.
Visser M, Verbaan D, van Rooden SM, Stiggelbout AM, Marinus J, van Hilten JJ. Assessment of psychiatric complications in Parkinson's disease: The SCOPA-PC. Mov Disord 2007;22:2221-8.  Back to cited text no. 49
    
50.
Lesieur HR, Blume SB. The South Oaks Gambling Screen (SOGS): A new instrument for the identification of pathological gamblers. Am J Psychiatry 1987;144:1184-8.  Back to cited text no. 50
    
51.
Driver-Dunckley E, Samanta J, Stacy M. Pathological gambling associated with dopamine agonist therapy in Parkinson's disease. Neurology 2003;61:422-3.  Back to cited text no. 51
    
52.
Burkhard PR, Catalano-Chiuvé S, Gronchi-Perrin A, Berney A, Vingerhoets FJ, Lüscher C. Impulse control disorders and Parkinson's disease. Rev Med Suisse 2008;4:1145-8.  Back to cited text no. 52
    
53.
Bastiaens J, Dorfman BJ, Christos PJ, Nirenberg MJ. Prospective cohort study of impulse control disorders in Parkinson's disease. Mov Disord 2013;28:327-33.  Back to cited text no. 53
    
54.
Mamikonyan E, Siderowf AD, Duda JE, Potenza MN, Horn S, Stern MB, et al. Long-term follow-up of impulse control disorders in Parkinson's disease. Mov Disord 2008;23:75-80.  Back to cited text no. 54
    
55.
Sohtaoǧlu M, Demiray DY, Kenangil G, Ozekmekçi S, Erginöz E. Long term follow-up of Parkinson's disease patients with impulse control disorders. Parkinsonism Relat Disord 2010;16:334-7.  Back to cited text no. 55
    
56.
Thomas A, Bonanni L, Gambi F, Di Iorio A, Onofrj M. Pathological gambling in Parkinson disease is reduced by amantadine. Ann Neurol 2010;68:400-4.  Back to cited text no. 56
    
57.
Walsh RA, Lang AE. Multiple impulse control disorders developing in Parkinson's disease after initiation of amantadine. Mov Disord 2012;27:326.  Back to cited text no. 57
    
58.
Weintraub D, Sohr M, Potenza MN, Siderowf AD, Stacy M, Voon V, et al. Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Ann Neurol 2010;68:963-8.  Back to cited text no. 58
    
59.
Hicks CW, Pandya MM, Itin I, Fernandez HH. Valproate for the treatment of medication-induced impulse-control disorders in three patients with Parkinson's disease. Parkinsonism Relat Disord 2011;17:379-81.  Back to cited text no. 59
    
60.
Bermejo PE. Topiramate in managing impulse control disorders in Parkinson's disease. Parkinsonism Relat Disord 2008;14:448-9.  Back to cited text no. 60
    
61.
Bermejo PE, Ruiz-Huete C, Anciones B. Zonisamide in managing impulse control disorders in Parkinson's disease. J Neurol 2010;257:1682-5.  Back to cited text no. 61
    
62.
Rotondo A, Bosco D, Plastino M, Consoli A, Bosco F. Clozapine for medication-related pathological gambling in Parkinson disease. Mov Disord 2010;25:1994-5.  Back to cited text no. 62
    
63.
Gerschlager W, Bloem BR. Managing pathological gambling in Parkinson's disease with enteral levodopa/carbidopa infusions. Mov Disord 2009;24:1858-60.  Back to cited text no. 63
    
64.
Todorova A, Samuel M, Brown RG, Chaudhuri KR. Infusion therapies and development of impulse control disorders in advanced Parkinson disease: Clinical experience after 3 years' follow-up. Clin Neuropharmacol 2015;38:132-4.  Back to cited text no. 64
    
65.
García Ruiz PJ, Sesar Ignacio A, Ares Pensado B, Castro García A, Alonso Frech F, Alvarez López M, et al. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: A multicenter study. Mov Disord 2008;23:1130-6.  Back to cited text no. 65
    
66.
Martinez-Martin P, Reddy P, Katzenschlager R, Antonini A, Todorova A, Odin P, et al. EuroInf: A multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson's disease. Mov Disord 2015;30:510-6.  Back to cited text no. 66
    
67.
Moore TJ, Glenmullen J, Mattison DR. Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs. JAMA Intern Med 2014;174:1930-3.  Back to cited text no. 67
    
68.
Ardouin C, Voon V, Worbe Y, Abouazar N, Czernecki V, Hosseini H, et al. Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation. Mov Disord 2006;21:1941-6.  Back to cited text no. 68
    
69.
Bandini F, Primavera A, Pizzorno M, Cocito L. Using STN DBS and medication reduction as a strategy to treat pathological gambling in Parkinson's disease. Parkinsonism Relat Disord 2007;13:369-71.  Back to cited text no. 69
    
70.
Shotbolt P, Moriarty J, Costello A, Jha A, David A, Ashkan K, et al. Relationships between deep brain stimulation and impulse control disorders in Parkinson's disease, with a literature review. Parkinsonism Relat Disord 2012;18:10-6.  Back to cited text no. 70
    
71.
Lhommée E, Klinger H, Thobois S, Schmitt E, Ardouin C, Bichon A, et al. Subthalamic stimulation in Parkinson's disease: Restoring the balance of motivated behaviours. Brain 2012;135(pt 5):1463-77.  Back to cited text no. 71
    
72.
Akakin A, Yilmaz B, Urgun K, Ekşi MS, Afşar N, Kiliç T. Hypersexuality after bilateral deep brain stimulation of the subthalamic nucleus for Parkinson's disease. Neurol India 2014;62:233-4.  Back to cited text no. 72
[PUBMED]  [Full text]  
73.
Kim YE, Kim HJ, Kim HJ, Lee JY, Yun JY. Impulse control and related behaviors after bilateral subthalamic stimulation in patients with Parkinson's disease. J Clin Neurosci 2013;20:964-9.  Back to cited text no. 73
    
74.
Hack N, Akbar U, Thompson-Avila A, Fayad SM, Hastings EM, Moro E, et al. Impulsive and compulsive behaviors in Parkinson Study Group (PSG) centers performing deep brain stimulation surgery. J Parkinsons Dis 2014;4:591-8.  Back to cited text no. 74
    
75.
Rogers RD, Wielenberg B, Wojtecki L, Elben S, Campbell-Meiklejohn D, Schnitzler A. Deep brain stimulation of the subthalamic nucleus transiently enhances loss-chasing behaviour in patients with Parkinson's disease. Exp Neurol 2011;231:181-9.  Back to cited text no. 75
    
76.
Moum SJ, Price CC, Limotai N, Oyama G, Ward H, Jacobson C, et al. Effects of STN and GPi deep brain stimulation on impulse control disorders and dopamine dysregulation syndrome. PLoS One 2012;7:e29768.  Back to cited text no. 76
    
77.
Galifianakis NB, Byrd EA, Ostrem JL, Tanner CM, Racine CA. Problematic mobile gaming in Parkinson's disease: An impulse control disorder for the smartphone. Movement Disorders in Clinical Practice 2017;4:277-8.  Back to cited text no. 77
    
78.
Wu K, Politis M, O'Sullivan SS, Lawrence AD, Warsi S, Lees A, et al. Problematic Internet use in Parkinson's disease. Parkinsonism Relat Disord 2014;20:482-7.  Back to cited text no. 78
    
79.
Perez-Lloret S, Rey MV, Fabre N, Ory F, Spampinato U, Montastruc JL, et al. Do Parkinson's disease patients disclose their adverse events spontaneously? Eur J Clin Pharmacol 2012;68:857-65.  Back to cited text no. 79
    
80.
Bhattacharjee S, Talbot JG, Vijayashankar P. Dopamine D3 receptor Ser9Gly variant is associated with impulse control disorders in Parkinson's disease patients. Parkinsonism Relat Disord 2017;34:69-70.  Back to cited text no. 80
    



 
 
    Tables

  [Table 1], [Table 2], [Table 3], [Table 4], [Table 5]



 

Top
Print this article  Email this article
   
Online since 20th March '04
Published by Wolters Kluwer - Medknow